Early trials of the drug VIR-5500 showed it shrinking tumours in some patients ...

The new drug, known as VIR-5500, uses a so-called cloaking device and only activates when it reaches the tumour ...

SYDNEY, Feb. 16, 2026 /PRNewswire/ -- Clarity Pharmaceuticals (ASX: CU6) ("Clarity" or "Company"), a clinical-stage radiopharmaceutical company with a mission to develop next-generation products that ...

A DRUG that shrinks tumours in patients with untreatable prostate cancer has shown “remarkable” results, scientists have said. The treatment, called VIR-5500, harnesses the body’s ...

Significantly less progression, especially unstable lesions, with relugolix versus leuprol ...

A drug for advanced prostate cancer has shown “remarkable” results in an early-stage trial, with patients who had previously stopped being receptive to treatment finding their tumours shrinking, ...

The methods of diagnosing and treating localised prostate cancer has changed significantly in the last two decades.

Step by step, little by little, we are learning how to act on this new staging information,’ one investigator says.

A drug for advanced prostate cancer has shown "remarkable" results in an early-stage trial, experts have said.

Blue Earth Diagnostics, a Bracco company and recognized leader in the development and commercialization of innovative positron emission tomography (PET) radiopharmaceuticals, today announced results ...